ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 675

Association Between Structural Lesions in the Sacroiliac Joints and Spinal Inflammatory Lesions in Patients with Non-Radiographic Axial Spondyloarthritis

Maxime Dougados1, Robert G Lambert2, Stephanie Wichuk3, Jean-Claude Becker4, Jack F Bukowski5, Heather Jones6, Lisa Marshall6, Annette Szumski7 and Walter Maksymowych3, 1Rheumatology, Paris Descartes University, Paris, France, 2Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 3Medicine, University of Alberta, Edmonton, AB, Canada, 4Becker Clinical Research Consulting, New York, NY, 5Clinical Affairs, Pfizer, Collegeville, PA, 6Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 7inVentiv Health, Princeton, NJ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: axial spondyloarthritis, Inflammation, MRI, non-radiographic and spine involvement

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The relevance of structural lesions in non-radiographic axial SpA (nr-axSpA) is unclear, particularly without signs of MRI inflammation. In a post hoc analysis we evaluated the association between structural lesions in the sacroiliac joints (SIJ) and spinal inflammatory lesions on MRI in early nr-axSpA. We hypothesized that structural lesions indicate a more extensive disease phenotype that includes early spinal involvement visible on MRI.

Methods: The EMBARK study (ClinicalTrials.gov: NCT01258738) enrolled patients 18-49 yrs old with axial SpA per ASAS imaging or clinical criteria without meeting modified New York radiographic criteria. Patients had symptoms for >3 months and <5 yrs, BASDAI score ≥4, and had failed ≥2 NSAIDs. Bone marrow edema (BME) in the SIJ and spine at baseline (BL) was assessed on short tau inversion recovery (STIR) scans by 2 independent readers using Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ and 23-DVU scores, respectively. BL structural lesions were evaluated on T1 weighted spin echo scans blinded to STIR scans, using the SPARCC MRI SIJ structural score (SSS). Univariate analysis evaluated the relationship between BL spinal inflammation and these BL characteristics: gender, presence/absence of any structural MRI lesions in the SIJ (SSS>0 or =0), presence/absence of specific MRI SIJ structural lesions, and SPARCC SIJ ≥2 or <2. Multivariate stepwise regression analysis evaluated the relationship between spinal inflammation and MRI SIJ lesions after including age, gender, and symptom duration.

Results: BL MRI scans were available for 185 patients. Mean (standard deviation [SD]) age was 32.0 (7.8) yrs, 60.5% were male, mean (SD) symptom duration was 2.4 (1.8) yrs, 133/182 (71.9%) patients were human leukocyte antigen B27+ and 152 (82.2%) met ASAS MRI imaging criteria. At BL, mean (SD) SPARCC MRI 23-DVU spinal score was 4.0 (8.0); 128/183 (69.9%) patients had SPARCC SIJ BME scores ≥2 and 55/183 (30.1%) had scores <2. A total of 77/185 (41.6%) patients had ≥1 structural lesion on MRI comprised of erosion (65/185, 35.1%), backfill (26/185, 14.1%), fat metaplasia (15/185, 8.1%) and ankylosis (4/185, 2.2%). Higher spine 23-DVU scores were observed in males, in the presence of definite SIJ inflammation (SPARCC SIJ ≥2, p=0.01), and in the presence of any one of the SIJ structural lesions, Table. Multivariate analysis indicated that erosion and backfill are independent factors associated with spinal inflammation; parameter estimates (SE): erosion: 2.9 (1.3), p=0.03; backfill: 3.9 (1.8), p=0.03.

Conclusion: MRI structural lesions in the SIJ occur in a substantial proportion of patients with nr-axSpA and their presence suggests a more extensive phenotype of disease associated with early spinal involvement.

Table. Univariate analysis of the relationship between spinal inflammation and select baseline characteristics, including MRI SIJ structural lesions, in patients with nr-axSpA

 

 

 

SPARCC spine score* at baseline

 

Baseline characteristic

Subgroup

N

Mean (SE)

Median (Q1, Q3)

P-value†

Gender

Female

76

2.4 (0.4)

1.0 (0, 3.0)

0.057

 

Male

114

5.5 (0.9)

2.0 (0, 6.5)

 

Ankylosis

0

170

4.3 (0.6)

1.5 (0, 5.0)

0.584

 

>0

4

9.0 (6.7)

3.8 (0.5, 17.5)

 

Erosion

0

112

3.0 (0.4)

1.5 (0, 4.0)

0.055

 

>0

62

6.9 (1.5)

2.0 (0.5, 7.0)

 

Any lesion

0

100

3.0 (0.4)

1.5 (0, 4.0)

0.082

 

>0

74

6.3 (1.3)

2.0 (0.5, 7.0)

 

Backfill

0

148

3.6 (0.5)

1.5 (0, 4.8)

0.237

 

>0

26

8.8 (3.0)

2.3 (0.5, 12.0)

 

Fat metaplasia

0

159

4.3 (0.7)

1.5 (0, 5.0)

0.338

 

>0

15

5.5 (1.9)

3.0 (0.5, 8.0)

 

SPARCC SIJ

<2

58

2.4 (0.5)

0.8 (0, 3.2)

0.013

 

≥2

132

5.1 (0.8)

2.0 (0.5, 6.3)

 

*SPARCC 23-dicovertebral units (DVU), 0-414 †from Wilcoxon-Mann-Whitney test Q, quartile; SE, standard error; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada

 


Disclosure: M. Dougados, Pfizer, AbbVie, Celgene, Eli Lilly, Novartis, Roche, and Sanofi-Aventis, 5,Pfizer, AbbVie, UCB, Merck, 8; R. G. Lambert, BioClinica, 5,Abbvie, 8; S. Wichuk, None; J. C. Becker, Own, 1,Becker Clinical Research Consulting, 3; J. F. Bukowski, Pfizer Inc, 1,Pfizer Inc, 3; H. Jones, Pfizer Inc, 1,Pfizer Inc, 3; L. Marshall, Pfizer Inc, 1,Pfizer Inc, 3; A. Szumski, inVentiv Health, 3; W. Maksymowych, Abbvie, 2,Janssen Pharmaceutica Product, L.P., 2,Pfizer Inc, 2,Sanofi-Aventis Pharmaceutical, 2,Abbvie, 5,Boehringer Ingelheim, 5,Eli Lilly and Company, 5,Celgene, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Sanofi-Aventis Pharmaceutical, 5,UCB, 5,Amgen, 5.

To cite this abstract in AMA style:

Dougados M, Lambert RG, Wichuk S, Becker JC, Bukowski JF, Jones H, Marshall L, Szumski A, Maksymowych W. Association Between Structural Lesions in the Sacroiliac Joints and Spinal Inflammatory Lesions in Patients with Non-Radiographic Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/association-between-structural-lesions-in-the-sacroiliac-joints-and-spinal-inflammatory-lesions-in-patients-with-non-radiographic-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-structural-lesions-in-the-sacroiliac-joints-and-spinal-inflammatory-lesions-in-patients-with-non-radiographic-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology